U.S. markets open in 2 hours 21 minutes

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
59.37-1.06 (-1.75%)
At close: 4:00PM EDT
Sign in to post a message.
  • T
    Tom
    No wonder why stock hits 52W low. Management spent lot of time and cash for the acquisition over last couple year while not focusing on existing promising pipelines and clinical trials. Two phase II trials were mismanaged and failed early this year due to operational mistake and ill does design.
  • j
    jon
    Im a buyer - just put them up for sale today !!
    Bullish
  • P
    Pablo Diablo
    How low can you go 🎵
    How low can you go 🎶
    📉
    ARNA doin the limbo today.
  • E
    ExperiencedBioPharmGuy
    Ugh. Not a fan of Arena investing in other companies and in licensing until it shows it can get its first program over the finish line. D- on this one Munshi.
  • B
    BOB
    Oh goody more free stock, I wonder when the investors will be rewarded, stock price from 90 down to 65 doesn't seem like much for investors. Although it looks as institutions are happy as they own more share than before.
  • E
    ExperiencedBioPharmGuy
    Down almost 2 dollars on...100K shares. No conviction to today's action.
  • E
    ExperiencedBioPharmGuy
    The JAK class is not going to work for Atopic Dermatitis but Etrasimod will - the combination of safety and efficacy will making choosing Etrasimod a no-brainer for dermatologists. Right now, the market has mistakenly analyzed the P2 results as poor - they were excellent and the P3 trial will show strong results when it is executed. This is why Etrasimod is a pipeline and why Arena's market cap is half of what it should be.
  • j
    jerry
    Amazing how the market is hitting highs and ARNA is hitting 52 week lows. Blaming mismanagement on this one.
  • j
    jerry
    Nearing the 52 week low, do you think we will break through to the downsize after the earnings? They can't be good. More spending with nothing to show for it. Amit/Jack is just playing the shareholder imo. Getting paid and dragging it on and on.
  • B
    BOB
    All is indices up through last 2 trading day's and we see Very low Volume and stock down.
  • B
    BOB
    Got to love the VILLAGE people and there need to get price down so they can cover as stating the institutional ownership is falling when everywhere I've looked it has increased. This stock is under attack as when indices were up this stock down on ultra low volume. Yes the insiders are wanting more shares also, yes down just like the village peoples leader lucky says. Almost time to buy more
  • B
    BOB
    Must be getting really close to news.
  • E
    Eren
    Loaded more on dips yesterday will keep
    Loading until the grand prize. I’m patient very patient if things pan out with our trial results sky is the limit. The industry needs an anti inflammatory that is not a steroid and I believe we Arena has the solution.
    Bullish
  • Y
    Yahoo Finance Insights
    Arena Pharmaceuticals is up 5.11% to 64.46
  • E
    ExperiencedBioPharmGuy
    Someone on IV was complaining about Arena having 300+ employees. There are 2 major pre-approval P3 programs right now: Ralinepag and Etrasimod. And Etrasimod is a pipeline in and of itself. And then there are several other compounds moving through earlier clinical stages. While it is a certainty that there is some waste at Arena, it is probably about average for the industry. Each product requires manufacturing, supply chain, clinical trial design and support and analysis, regulatory support, validation (of facilities, utilities, systems, processes, and methods,) and more. The company needs finance, legal, and the start of marketing and sales organizations. Everything is made more complex by needing to comply with each country and economic community's requirements. For example, EMEA, Switzerland, Japan, Canada, and the USA all have different complaint handling requirements and workflows. While most have lined up behind a united effort to simplify filings (such as eCTDs and the ICH), there are still significant difference between area/country requirements. And reimbursement negotiations are a quagmire that is for a team not a person. Anyone who thinks Arena could get by with 20% of headcount is way off base. And the cries about Amit being worse than any other self-interested biopharm CEO seem racist to me: he is greedy, for sure, and so are all the shareholders who are complaining about his.
  • J
    Joseph
    Bought more today, right at the Fibonacci 38.2 retracement point.
  • P
    Pablo Diablo
    Raise your hand if your position lost over 5 thousand today 🙋‍♂️
  • K
    Kim
    New inducement grants/free shares for the hard workers!!!
    I'm stunned 🤣
  • E
    ExperiencedBioPharmGuy
    Very, very low volume on the downdrafts, more volume on the updrafts. Only took 12K shares to drop share price $1.60 and now only down 36 cents...despite only 75K total shares traded by 230PM.
  • j
    jerry
    Jack played games with us for years. Now it looks like Amit is doing the same thing. Losing hope in management. Looks like hedge funds are too. Down we go!